Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
next major event unfolding is the UK MHRA decision for HMTM by TauRx. Genting has ~20% stakes in it. The decision should be available by Dec'24 assuming the 150 days approval process is followed accordingly and Jul'24 is the acceptance date for the data from the clinical trials submitted by TauRx to UK MHRA. Quite a number of controversies on recently approved Alzheimer drugs by the FDA, lecanemab and donanemab. The biggest concerns are coming from the safety perspective due to the adverse events observed during the trials.
let the authority in UK MHRA decide whether the data submitted is good or not :) We will know in 3 months time. As for fund managers, they will do their part when the decision is available. If it is approved, the analysts working for the funds/insti will perform necessary valuations to determine how much it is worth based on the assumptions of in-source, outsource and m&a. As TauRx is a research company, it is probably that the marketing authorization will probably be acquired by big pharma with manufacturing facilities.
well, there is also Temasek the substantial shareholder of TauRx. Genting is just 20% ownership. Temasek's investment is probably 3x of Genting's investment.
No worries, TN. Research companies have to continue research in the field of medicine even if it fails. When they are successful in their research, the big pharma will step in to buy the rights and to mass produce it.
I dont see anything wrong with the descriptions, TN. What is important is the results from the clinical trials - the safety and efficacy of the drugs. And decision from regulatory authorities for marketing authorization. Different country different authorities - UK MHRA for UK, FDA for US, EMA for Europe and etc. Lets not second guess the adverse events as there is none reported from the clinical trials participants for HMTM. Please feel free to send it to me if you have noticed or read about adverse events treatment required for HMTM clinical trials participants. I am interested to read it as there were lots of concerns from the recently approved Alzheimer drugs from the big pharma. Thanks for the sharing on averaging down. I am aware of the risks associated with sin stocks; so far so good. I have just initiated position recently and will definitely add again if opportunity arises.
Keep wait n wait for this counter...
Share price doesn't move much...
CNY soon around 3 month left...
Hope LKT can gv us big ang pao...
Patient is key now!
